

Carocell Bio

Developing Novel Therapeutics for Inflammatory Diseases

Our goal is to develop and deliver the next generation of anti-inflammatory therapeutics to treat and improve the lives of patients living with inflammatory disease

Seeking staged investment over the next 3 years to take our peptide combination molecules through preclinical development to the clinic

Contact the Executive Team for further information

Carocell Bio's Development Pipeline

Anti-inflammatory Peptides

- Portfolio of peptide MAPK (p38 α) inhibitors
- Initially developed by AstraZeneca
- Exclusively licensed to Carocell Bio in Q4 2017

Using combination technology to improve efficacy and safety outcomes



Intracellular Peptide Delivery System

- Nanocin™ drug reformulation technology, developed by Tecrea
- Forms nanoparticles with the peptides
- Significantly enhances their penetration into cells
- Used in a range of marketed products, e.g. eye drops, wound dressings
- Long and positive safety record

Unique Proposition for the Treatment of Inflammation

MODE OF ACTION

Unique MOA

Peptide + delivery system combination

Different MOA to small molecules

Combination forms stable alpha helices

Blocks p38a activation and reactivation

Allosteric binding: attaches close to the phosphorylation site

Reduces pro-inflammatory cytokine production

ADMINISTRATION

Topical, not systemic

Soothing, therapeutic creams for skin conditions

Gel/delayed release oral capsule for IBD

DOSE

Low doses

High target selectivity and potency

High intracellular levels (Nanocin delivery system)

Unique Proposition for the Treatment of Inflammation

EFFICACY

Potent inflammation inhibitor

Ability to 'halt' inflammation at the top of the intracellular inflammation cascade

Highly effective

SAFETY

Simple safety profile

Rapidly broken down into amino acids in serum

No liver toxicity

INDICATIONS

Improved therapeutic option


AD: Instead of steroid creams

IBD: Before biologics


First-line in patients with mild-to-moderate symptoms

Intracellular Inflammatory Cascade

Target for p38 α inhibitors, high up in the inflammatory cascade




Inflammatory Conditions Need Improved Therapies



Building a global pyramid of IP protection

- Strong, worldwide IP protection to 2036
 - US: US10.293,029, granted May 2019
 - Japan: 100106002, granted August 2019
 - EU: filed and pending (est. Q1 2020)
 - China: filed and pending
- Nanocin Patent WO2013054123

Seeking Investment for Development



*Phased investment options available

CTA, clinical trial authorization; GMP, good manufacturing practice; GxP, good practice; NDA, new drug application; IND, investigational new drug


Carocell Bio Executive Team

Dr Mike Davies MD, FRCRS, FRSPSG CEO & Founder



- Over 25 years' global executive leadership experience in drug development in pharma (Pfizer, AstraZeneca, Shire) and biotech
- Expertise in early-stage development and taking medicines from ideation to the market
- Founder of Carocell Bio

Patrick Doyle Chairman



- Over 20 years' global executive leadership experience in pharma (Novo Nordisk, Roche) and biotech
- Expertise in executing productive licenses and alliances across organizations
- Start-up and biotech leadership including business development and R&D strategic development

Carocell Bio Advisory Team

Professor John Mclaughlin
Scientific Advisor, IBD

Professor of Gastroenterology and Nutrition, Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, University of Manchester, UK

Professor Mamta Shah
Scientific Advisor, burns

Professor of Children's Burn and Plastic Surgeon, Manchester Centre for Plastic Surgery and Burns, University Hospital of South Manchester, UK

John Nicholson
Business Advisor

International experience in the pharmaceutical and chemical industries; funded and managed Analytical Services companies. Advisory Board member of the UK North West Business Fund

Carocell Bio Team

- **Sue Streatfield, LLP**
Partner at Clarion Solicitors, Leeds
Expertise in intellectual property rights, R&D agreements, licences and assignments, trademarks and designs
- **Simon Bradbury**
Partner at Appleyard Lees, Manchester
Expertise in intellectual property in life sciences and biotechnology sector
- **Ruth James, AAC**
Partner at Nolan James Chartered Accountants, Poynton
- **Dave Black**
Partner at Onside Creative
Expertise in design and digital technologies
- **Shirley Smith, BSc**
Partner at SJS Biocommunications
Expertise in scientific communications
- **Jane Davies RN, RM**
Project Manager
Expertise in project management

Summary

Carocell Bio is committed to bringing innovative new therapeutic options into the inflammation space

Seeking staged investment over the next 3 years to take our peptide combination molecules through preclinical development to the clinic

Contact the Executive Team for further information

Contact Us

Dr Mike Davies MD, FRCS, FRCPSG
CEO & Founder

UK: +44 (0)7740 188500
US: +1 212 863 9902
mike.davies@carocellbio.com

Patrick Doyle
Chairman

US: +1 646 519 0459
patrick.doyle@carocellbio.com



Thank you